Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: I2 Clear all
Completed Phase 2 Interventional Results available

Management of Insomnia in Breast Cancer Patients

NCT01011218
View directory record Official record
Conditions
Insomnia, Fatigue
Interventions
BBT-I, Control, Armodafinil
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 2, 2026, 10:31 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)

NCT06682650
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
NPT-PLA, Usual Quality Improvement
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Not applicable Interventional

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

NCT02676336
View directory record Official record
Conditions
Fibrocystic Breast Condition (FBC)
Interventions
Violet™ Molecular Iodine (I2), Placebo
Dietary Supplement · Other
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

NCT02395978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule, placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
3,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
116
States / cities
Phoenix, Arizona • Downey, California • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

NCT04347954
View directory record Official record
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 2, 2026, 10:31 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

NCT00000327
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

NCT03988907
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Risdiplam, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 2, 2026, 10:31 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

NCT04194554
View directory record Official record
Conditions
Prostate Cancer
Interventions
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations

NCT03100461
View directory record Official record
Conditions
Colorectal Cancer
Interventions
I2, Health Education
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NCT03794544
View directory record Official record
Conditions
Resectable, Early-stage, NSCLC
Interventions
Durvalumab, Oleclumab, Monalizumab, Danvatirsen
Drug · Combination Product
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 102 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
La Jolla, California • Fort Myers, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

NCT01689623
View directory record Official record
Conditions
Healthy Participants
Interventions
TMC435, Atorvastatin, Simvastatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

NCT02373930
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ, DTG/RPV 50 mg/25 mg: Product Code AK, DTG/RPV 50 mg/25 mg: Product Code AR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Navigation to Improve ADHD Treatment Adherence for Minority Children

NCT04591951
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
I2-ART, Usual care
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

NCT01084252
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Isatuximab SAR650984, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 2, 2026, 10:31 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Neural Constraints on Movement in Stroke

NCT06666673
View directory record Official record
Conditions
Stroke
Interventions
Tizanidine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 10:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

NCT03041324
View directory record Official record
Conditions
Mucopolysaccharidosis II, MPS II
Interventions
SB-913
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
5 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 4 Interventional Results available

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

NCT04969250
View directory record Official record
Conditions
Covid19
Interventions
Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685
View directory record Official record
Conditions
Healthy
Interventions
AZD2624
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 2, 2026, 10:31 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

NCT00453388
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Oakland, California • Nashville, Tennessee • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 2, 2026, 10:31 PM EDT
Not yet recruiting Phase 2 Interventional

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

NCT07720167
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 2, 2026, 10:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

NCT02702115
View directory record Official record
Conditions
MPS I
Interventions
SB-318
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
5 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 2, 2026, 10:31 PM EDT